Day Return
YTD Return
1-Year Return
3-Year Return
5-Year Return
Note: Sector performance is calculated based on the previous closing price of all sector constituents
Industries in This Sector
Select an Industry for a Visual Breakdown
Industry | Market Weight | Day Return | YTD Return |
---|---|---|---|
All Industries | 100% | -0.12% | 1.71% |
Drug Manufacturers - General | 34.23% | 1.42% | 7.81% |
Healthcare Plans | 13.30% | -0.63% | -5.72% |
Medical Devices | 12.90% | -0.97% | 3.24% |
Diagnostics & Research | 11.44% | -1.15% | 1.83% |
Biotechnology | 11.04% | -1.03% | -8.52% |
Medical Instruments & Supplies | 6.66% | -0.68% | 2.30% |
Medical Care Facilities | 2.92% | 0.55% | 9.58% |
Drug Manufacturers - Specialty & Generic | 2.76% | 0.20% | -6.17% |
Medical Distribution | 2.43% | -0.78% | 10.13% |
Health Information Services | 2.09% | -4.07% | 4.38% |
Pharmaceutical Retailers | 0.24% | -1.44% | -31.76% |
Note: Percentage % data on heatmap indicates Day Return
All Industries
-
Largest Companies in This Sector
Name
|
Last Price
|
1Y Target Est.
|
Market Weight
|
Market Cap
|
Day Change %
|
YTD Return
|
Avg. Analyst Rating
|
---|---|---|---|---|---|---|---|
781.10 | 826.94 | 11.73% |
|
|
|
Buy
|
|
483.70 | 566.61 | 7.03% |
|
|
|
Buy
|
|
144.59 | 173.75 | 5.50% |
|
|
|
Buy
|
|
129.22 | 141.02 | 5.17% |
|
|
|
Buy
|
|
162.64 | 183.53 | 4.55% |
|
|
|
Buy
|
|
568.72 | 619.07 | 3.43% |
|
|
|
Buy
|
|
105.97 | 126.69 | 2.90% |
|
|
|
Buy
|
|
246.62 | 271.39 | 2.89% |
|
|
|
Buy
|
|
273.94 | 306.20 | 2.32% |
|
|
|
Buy
|
|
25.62 | 31.10 | 2.29% |
|
|
|
Buy
|
Investing in the Healthcare Sector
Start Investing in the Healthcare Sector Through These ETFs and Mutual Funds
ETF Opportunities
Name
|
Last Price
|
Net Assets
|
Expense Ratio
|
YTD Return
|
---|---|---|---|---|
140.33 | 41.319B | 0.09% |
|
|
256.04 | 21.195B | 0.10% |
|
|
126.92 | 7.632B | 0.45% |
|
|
84.62 | 7.551B | 0.35% |
|
|
55.01 | 5.76B | 0.40% |
|
Mutual Fund Opportunities
Name
|
Last Price
|
Net Assets
|
Expense Ratio
|
YTD Return
|
---|---|---|---|---|
207.37 | 47.432B | 0.29% |
|
|
87.44 | 47.432B | 0.29% |
|
|
128.14 | 21.195B | 0.10% |
|
|
90.17 | 15.399B | 0.80% |
|
|
92.74 | 15.399B | 0.80% |
|
Healthcare Research
Discover the Latest Analyst and Technical Research for This Sector
-
Analyst Report: Aurora Cannabis Inc.
Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements.
RatingPrice Target -
Analyst Report: Coloplast A/S
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, paste, powder, seals, and intermittent catheters for continence care. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
RatingPrice Target -
Analyst Report: Curaleaf Holdings, Inc.
Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the US. The company has operations in 17 states. Its brands include Curaleaf, Select, and Grassroots. The company has made acquisitions that give it exposure to the growing European market, a unique feature among US multistate operators.
RatingPrice Target -
Analyst Report: Cronos Group Inc.
Cronos Group, headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S. the company has an option to acquire 10.5% of U.S. multistate operator PharmaCann upon easing of federal prohibition.
RatingPrice Target